Dr. Reddy’s Faces U.S. Court Complaint Over Revlimid Sales Antitrust Allegations

10 Oct 2023 , 12:15 PM

Dr. Reddy’s Laboratories faces a complaint in a U.S. court over the sale of the cancer drug Revlimid, with its subsidiary named as a defendant. Mayo Clinic and Lifepoint Corporate Services, along with several pharmaceutical companies, filed the complaint alleging antitrust violations and maintaining a shared monopoly in Revlimid sales through patent litigation settlements.

The complaint, filed on October 6 in the United States District Court for the Northern District of California, claims improper delays in generic entry until 2022 and restrictions on generic competition until 2026. Dr. Reddy’s contests the allegations, stating they lack merit, and vows to vigorously defend against the litigation.

This follows a similar complaint in November 2022, naming Dr. Reddy’s and others, including Celgene and Bristol Myers Squibb, as defendants, asserting similar antitrust claims regarding Revlimid sales. In a December update, Dr. Reddy’s announced the dismissal of all claims against the company in the antitrust litigation.

For feedback and suggestions, write to us at [e-mail]